Acta chirurgica Austriaca

, Volume 25, Issue 3, pp 159–162

Langzeitergebnisse der Skelerosierungs-therapie bei Patienten mit portaler Hypertension

  • T. Sauerbruch
Themenschwerpunkt: Neue Trends in der Therapie der Portalen Hypertonie Therapie
  • 7 Downloads

Zusammenfassung

Mit Einführung der flexiblen Endoskopie kam es zu einer zunehmenden Ausbreitung der Sklerosierungsbehandlung von Ösophagusvarizen. Die notfallmäßige unterspritzung der Ösophagusvarizen ist nach den vorliegenden kontrollierten Studien die beste Methode, um eine akute Blutstillung zu erreichen. Dagegen ist die Langzeitsklerosierungstherapie mit einer Rezidivblutungsfrequenz von 30 bis 40% belastet. Sie verhindert die wiederholte Blutung weniger effizient als eine portokavale Shunt-Operation. Gleichwohl werden die Probleme der Shunt-Operation (akute Operationsletalität, hepatische Enzephalopathie oder protrahiertes postoperatives Leberversagen) vermieden, so daß primär zunächst immer eine Langzeitsklerosierungstherapie angestrebt werden kann. Die chronische Behandlung mit nichtselektiven Beta-Blockern ist einer wiederholten Verödungstherapie bezüglich Rezidivblutungsfrequenz und Überleben vergleichbar. Daher kann nach akutem Blutungsstopp durch Injektion der Varizen durchaus individuell und abhängig vom Krankheitsverlauf vorgegangen werden. Zur Prophylaxe der ersten Ösophagusvarizenblutung sollte die Skelerosierungstherapie nur innerhalb kontrollierter Studien eingesetzt werden.

Schlüsselwörter

Sklerosierungstherapie Ösophagusvarizen 

Results of longterm injection sclerotherapy in patients with portal hypertension

Summary

The introduction of flexible endoscopy has led to numerous controlled and uncontrolled trials with respect to sclerotherapy of esophageal varices. According to randomized controlled trials injection sclerotherapy is the most successful method to achieve hemostasis of acute variceal bleeding. By contrast, long-term injection sclerotherapy with the aim of eradication of varices has the problem of recurrent bleeding in around 40% of patients. Therefore, recurrent bleeding is prevented less efficiently than by a portal systemic shunt operation. However, shunt surgery may be complicated by surgical fatalities, hepatic encephalopathy or late liver failure. These problems can be prevented if long-term sclerotherapy is the first therapeutic step which surgery as salvage in case of recurrent bleeding. According to controlled trials, the chronic intake of the a nonselective betablocker (propranolol) is equally effective to sclerotherapy in the prevention of rebleeding. Therefore, different treatment options should be considered according to the needs of the individual patient after hemostasis of acute esophageal variceal bleeding has been achieved. Prophylaxis of first variceal hemorrhage can only be recommended for patients who take part in controlled trials.

Key-words

Sclerotherapy esophageal varices 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. (1).
    Calès P, Pascal JP: Histoire naturelle des varices oesophagiennes au cours de la cirrhosis (de la naissance à la rupture). Gastroenterol Clin Biol 1988;12:245–253.PubMedGoogle Scholar
  2. (2).
    D'Amico G, Montalbano L, Traina M, et al: Natural history of congestive gastropathy in cirrhosis. Gastroenterology 1990;99:1558–1564.PubMedGoogle Scholar
  3. (3).
    Poynard T, Calès P, Pasta L, et al: Beta adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532–1538.CrossRefPubMedGoogle Scholar
  4. (4).
    Sauerbruch T, Wotzka R, Köpcke W, et al: Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. N Engl J Med 1988;319:8–15.CrossRefPubMedGoogle Scholar
  5. (5).
    Barsoum MS, Bolour FI, El-Rooby AA, Risk-Altah MA, Ibrahim AS: Tamponade and injection sclerotherapy in the management of bleeding oesophageal varices. Br J Surg 1982;69:76–78.CrossRefPubMedGoogle Scholar
  6. (6).
    Paquet KJ, Feussner H: Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophagegastric varices: a prospective controlled randomized trial. Hepatology 1985;5:580–583.CrossRefPubMedGoogle Scholar
  7. (7).
    Westaby D, Hayes PC, Gimson AES, Polson RJ, Williams R: Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989;9:274–277.CrossRefPubMedGoogle Scholar
  8. (8).
    Di Febo G, Siringo M, Vacirca M, et al: Somatostatin (SMS) and urgent sclerotherapy (US) in active oesophageal variceal bleeding. Gastroenterology 1990;98:A583 (abstr).Google Scholar
  9. (9).
    Chung RS, Dearlove MS: The sources of recurrent hemorrhage during long-term sclerotherapy: Surgery 1988;104:687–696.PubMedGoogle Scholar
  10. (10).
    De Franchis R, Vitagliano P, Agape D, et al: Eradication of esophageal varices by endoscopic sclerotherapy: how much is enough? Gastrointest Endosc 1988;34:395–399.CrossRefPubMedGoogle Scholar
  11. (11).
    Sauerbruch T, Fischer G, Ansari H: Variceal injection sclerotherapy. Baillière's Clin Gastroenterol 1991;5:131–153.CrossRefGoogle Scholar
  12. (12).
    Terblanche K, Kahn D, Campbell JAH, et al: Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial. Lancet 1983;II:1328–1332.CrossRefGoogle Scholar
  13. (13).
    Dilawari JB, Raju GS, Chawla YK: Development of large spleno-adreno-renal shunt after endoscopic sclerotherapy. Gastroenterology 1989;97:421–426.CrossRefPubMedGoogle Scholar
  14. (14).
    Korula J, Ralls P: The effects of chronic endoscopic variceal sclerotherapy on portal pressure in cirrhosis. Gastroenterology 1991;101:800–805.CrossRefPubMedGoogle Scholar
  15. (15).
    Soehendra N, Grimm H, Nam VC, Berger B: N-butyl 2-cyanoacrylate: a supplement to endoscopic sclerotherapy. Endoscopy 1987;19:221–224.CrossRefPubMedGoogle Scholar
  16. (16).
    Ramond MJ, Valla D, Mosnier JF, et al: Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology 1989;10:488–493.CrossRefPubMedGoogle Scholar
  17. (17).
    Polson RJ, Westaby D, Gimson AES, et al: Sucralfate for the prevention of early rebleeding following injection sclerotherapy for escophageal varices. Hepatology 1989;10:279–282.CrossRefPubMedGoogle Scholar
  18. (18).
    Tabibian N, Smith JS, Graham DY: Sclerotherapy associated ulcers: lessons from a double-blind, randomized comparison of sucralfate suspension versus placebo. Gastrointest Endosc 1989;35:312–315CrossRefPubMedGoogle Scholar
  19. (19).
    Snady H, Rosman AS, Korsten MA: Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices. Gastrointest Endosc 1989;35:312–315.CrossRefGoogle Scholar
  20. (20).
    Stoltenberg PH, Goodale RL, Silvis SE: Portal vein thrombosis following combined endoscopic variceal sclerosis and vasopressin therapy for bleeding varices. Am J Gastroent 1987;82:1297–1300.PubMedGoogle Scholar
  21. (21).
    Goldberg H, Fabry TL: Mesenteric thrombosis following sclerotherapy during vasopressin infusion: mechanism and therapeutic implications. J Clin Gastroenterol 1989;11:56–57.CrossRefPubMedGoogle Scholar
  22. (22).
    Cello JP, Grendell JH, Grass RA, Weber TE, Trunkey DD: Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. N Engl J Med 1987;316:11–15.CrossRefPubMedGoogle Scholar
  23. (23).
    Rikkers LF, Burnett DA, Volentine GD, Buchi KN, Cormier RA: Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Ann Surg 1987;206:261–271.CrossRefPubMedPubMedCentralGoogle Scholar
  24. (24).
    Terés J, Bordas JM, Bravo D, et al: Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology 1987;7:430–436.CrossRefPubMedGoogle Scholar
  25. (25).
    Spina GP, Santambrogio R, Opocher E, et al: Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized controlled trial. Ann Surg 1990;211:178–186.CrossRefPubMedPubMedCentralGoogle Scholar
  26. (26).
    Henderson JM, Kuntner MH, Millikan WJ, et al: Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis. A prospective randomized trial. Ann Int Med 1990;112:262–269.CrossRefPubMedGoogle Scholar
  27. (27).
    Huizinga WKJ, Angorn IB, Baker LW: Esophageal transection versus injection sclerotherapy in the management of bleeding esophageal varices in patients at high risk. Surg Gynecol Obstet 1985;160:539–546.PubMedGoogle Scholar
  28. (28).
    Terés J, Baroni R, Bordas JM, et al: Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987;4:159–167.CrossRefPubMedGoogle Scholar
  29. (29).
    Burroughs AK, Hamilton G, Phillips A, et al: A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices. N Engl J Med 1989;321:857–862.CrossRefPubMedGoogle Scholar
  30. (30).
    Westaby D, Melia WM, Macdougall BRD, et al: β1 selective adrenoreceptor blockade for the long term management of variceal bleeding. A prospective randomized trial to compare oral metroprolol with injection sclerotherapy in cirrhosis. Gut 1985;26:421–425.CrossRefPubMedPubMedCentralGoogle Scholar
  31. (31).
    Fleig WE, Stange EF, Hunecke R, et al: Prevention of recurrent bleeding in cirrhosis with recent variceal hemorrhage: prospective randomized comparison of progranolol and sclerotherapy. Hepatology 1987;7:355–361.CrossRefPubMedGoogle Scholar
  32. (32).
    Alexandrino PT, Alves MM, Correia JP: Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding. A prospective, randomized controlled trial. J Hepatol 1988;7:175–185.CrossRefPubMedGoogle Scholar
  33. (33).
    Dollet JM, Champigneulle B, Patris A, Bigard MA, Gaucher P: Sclérothérapie endoscopique contre propranolol après hémorrhage par rupture de varices oesophagiennes chez le cirrhotique. Résultats à 4 ans d'une étude randomisée. Gastroenterol Clin Biol 1988;12:234–239.PubMedGoogle Scholar
  34. (34).
    Westaby D, Polson RJ, Gimson AES, et al: A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology 1990;11:353–359.CrossRefPubMedGoogle Scholar
  35. (35).
    Paquet KJ: Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices—a prospective controlled randomized trial. Endoscopy 1982;14:4–5.CrossRefPubMedGoogle Scholar
  36. (36).
    Witzel L, Wolbergs E, Merki H: Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlled study. Lancet 1985;I:773–775.CrossRefGoogle Scholar
  37. (37).
    Koch H, Henning H, Grimm H, Soehendra N: Prophylactic sclerosing of esophageal varices results of a prospective controlled study. Endoscopy 1986;18:40–43.CrossRefPubMedGoogle Scholar
  38. (38).
    Wördehoff D, Spech HJ: Prophylaktische Ösophagusvarizensklerosierung. Dtsch Med Wschr 1987;112:947–951.CrossRefPubMedGoogle Scholar
  39. (39).
    Santangelo CW, Dueno MI, Estes BL, Krejs GJ: Prophylactic sclerotherapy of large esophageal varices. N Engl J Med 1988;318:814–818.CrossRefPubMedGoogle Scholar
  40. (40).
    Piai G, Cipolletta L, Claar M, et al: Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial. Hepatology 1988;8:1495–1500.CrossRefPubMedGoogle Scholar
  41. (41).
    Pötzi R, Bauer P, Reichel W, et al: Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. A multicentre prospective controlled randomized trial in Vienna. Gut 1989;30:873–879.CrossRefPubMedPubMedCentralGoogle Scholar
  42. (42).
    Russo A, Giannone G, Magnano A, Passanisis G, Longo C: Prophylactic sclerotherapy in nonalcoholic liver cirrhosis: preliminary results of a prospective controlled randomized trial. World J Surg 1989;13:149–153.CrossRefPubMedGoogle Scholar
  43. (43).
    Kobe E, Zipprich B, Schentke KU, Nilius R: Prophylactic endoscopic sclerotherapy of esophageal varices—a prospective randomized trial. Endoscopy 1990;22:245–248.CrossRefPubMedGoogle Scholar
  44. (44).
    Andreani T, Poupon RE, Balkau BJ, et al: Preventive therapy with propranolol of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology 1990;12:1413–1419.CrossRefPubMedGoogle Scholar
  45. (45).
    VACVSG (Veterans Affairs Cooperative Variceal Sclerotherapy Group): Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. N Engl J Med 1991:324:1779–1784.CrossRefGoogle Scholar
  46. (46).
    Triger DR, Smart HL, Hosking SW, Johnson AG: Prophylactic sclerotherapy for esophageal varices: long-term results of a single-center trial. Hepatology 1991;13:117–123.CrossRefPubMedGoogle Scholar
  47. (47).
    De Franchis R, Primignani M, Arcidiacono PG, et al: Prophylactic sclerotherapy in high-risk cirrhotics selected by endoscopic criteria. A multicenter randomized controlled trial. Gastroenterology 1991;101:1087–1093.CrossRefPubMedGoogle Scholar
  48. (48).
    Kleber G, Ansari H, Sauerbruch T: Prophylactic of first variceal bleeding. Baillère Tindall, 1992 (in press).Google Scholar
  49. (49).
    Pape GR, Sauerbruch T: Leberkrankheiten, in Riecker G et al (eds). Therapie innerer Krankheiten 7 Aufl. Berlin-Heidelberg-New York. Springer, 1991, p 733–771.CrossRefGoogle Scholar

Copyright information

© Blackwell Scientific Publications Ltd 1992

Authors and Affiliations

  • T. Sauerbruch
    • 1
  1. 1.Allgemeine Innere MedizinMedizinische UniversitätsklinikBonn-VenusbergDeutschland

Personalised recommendations